Healthcare -
Biotechnology - NASDAQ - DE
$ 5.45
0.926 %
$ 1.23 B
Market Cap
5.92
P/E
1. INTRINSIC VALUE
Balance Sheet
CureVac N.V.
| Current Assets | 526 M |
| Cash & Short-Term Investments | 485 M |
| Receivables | 32.9 M |
| Other Current Assets | 8.14 M |
| Non-Current Assets | 276 M |
| Long-Term Investments | 0 |
| PP&E | 245 M |
| Other Non-Current Assets | 31.8 M |
| Current Liabilities | 72.3 M |
| Accounts Payable | 17.3 M |
| Short-Term Debt | 5.32 M |
| Other Current Liabilities | 49.8 M |
| Non-Current Liabilities | 33.9 M |
| Long-Term Debt | 33.6 M |
| Other Non-Current Liabilities | 227 K |
EFFICIENCY
Earnings Waterfall
CureVac N.V.
| Revenue | 535 M |
| Cost Of Revenue | 106 M |
| Gross Profit | 429 M |
| Operating Expenses | 252 M |
| Operating Income | 178 M |
| Other Expenses | -13.2 M |
| Net Income | 191 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CureVac N.V.
| Net Income | 191 M |
| Depreciation & Amortization | 18.8 M |
| Capital Expenditures | -18.4 M |
| Stock-Based Compensation | 4.12 M |
| Change in Working Capital | -164 M |
| Others | 16.6 M |
| Free Cash Flow | 83.4 M |
Wall Street Analysts Price Targets
CureVac N.V.
Wall Street analysts predict an average 1-year price target for CVAC of $17 , with forecasts ranging from
a
low of
$5 to a high of $37 .
CVAC Lowest Price Target
Wall Street Target
5 USD
-8.26%
CVAC Average Price Target
Wall Street Target
17 USD
211.93%
CVAC Highest Price Target
Wall Street Target
37 USD
578.90%
4. DIVIDEND
ANALYSIS
CVAC does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CureVac N.V.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting.
accessnewswire.com
- 2 weeks ago
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
zacks.com
- 2 weeks ago
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating CureVac N.V. (NASDAQ: CVAC ) related to its sale to BioNTech SE. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. Is it a fair deal?
globenewswire.com
- 2 weeks ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
globenewswire.com
- 3 weeks ago
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow Jones Industrial Average was lower.
investopedia.com
- 3 weeks ago
CureVac Stock Soars on BioNTech Buyout
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
schaeffersresearch.com
- 3 weeks ago
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
benzinga.com
- 3 weeks ago
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, each share of CureVac will be exchanged for about $5.46 worth of BioNTech American Depositary Shares (ADSs), representing a premium of around 55% over CureVac's recent trading price.
proactiveinvestors.com
- 3 weeks ago
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. Halper Sadeh encourages CureVac shareholders to click here to learn more a.
businesswire.com
- 3 weeks ago
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
CureVac stock soared 29% $5.26 in premarket trading immediately following the news.
barrons.com
- 3 weeks ago
BioNTech to acquire CureVac in $1.25 billion all-stock deal
German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.
reuters.com
- 3 weeks ago
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial Application filed in Europe with decision expected in Q2 2025 Glioblastoma study fully enrolled with Part B of Phase 1 CVGBM trial completing enrolment in Q1 2025; go/no-go decision on moving to Phase 2 planned for H2 2025 First urinary tract infection vaccine moving forward with U.S. IND filing planned for H2 2025 Core mRNA patents upheld as European Patent Office confirmed validity of two key patents in amended form; infringement hearing against BioNTech/Pfizer before the Regional Court Düsseldorf set for July 1, 2025 Strong cash and cash equivalents position of €438.3 million as of March 31, 2025; reaffirming expected cash runway into 2028 TÜBINGEN, GERMANY and BOSTON, MA / ACCESS Newswire / May 20, 2025 / CureVac N.V. (Nasdaq:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced financial results for the first quarter of 2025 and provided a business update.
accessnewswire.com
- 1 month ago
8. Profile
Summary
CureVac N.V. CVAC
COUNTRY
DE
INDUSTRY
Biotechnology
MARKET CAP
$ 1.23 B
Dividend Yield
0.00%
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Contact
Friedrich-Miescher-Strasse 15, Tübingen, 72076
https://www.curevac.com
IPO
Date
Aug. 14, 2020
Employees
825
Officers
Mr. Thaminda Ramanayake
Chief Business Officer & Member of Executive Board
Dr. Patrick Baumhof
Senior Vice President of Technology
Mr. Marco Rau L.L.M., Ph.D.
General Counsel
Dr. Sarah Fakih
Vice President Corporate Communications & Investor Relations
Dr. Alexander Zehnder M.B.A., M.D.
Chief Executive Officer, MD & Member of Management Board
Mr. Axel-Sven Malkomes
Chief Financial Officer & Member of Executive Board
Dr. Malte Greune Ph.D.
Chief Operating Officer, Member of Management Board & MD
Dr. Myriam Mendila M.D.
Chief Scientific Officer, Head of R&D, MD & Member of the Management Board
Slavica Stevanovic-Heck
Head of Human Resources
Dr. Ulrike Gnad-Vogt M.D., Ph.D.
Senior Vice President & Area Head of Oncology